声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。11月19日,CDE网站显示,百济神州申报的1类新药BGB-58067片获得临床试验默示许可,拟开发治疗晚期实体瘤患者。根据百济神州公开资料,BGB-58067是一款PRMT5抑制剂,为百济神州未来的核心项目之一。根据CDE官网查询,这是该产品首次在中国...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。11月19日,CDE网站显示,百济神州申报的1类新药BGB-58067片获得临床试验默示许可,拟开发治疗晚期实体瘤患者。根据百济神州公开资料,BGB-58067是一款PRMT5抑制剂,为百济神州未来的核心项目之一。根据CDE官网查询,这是该产品首次在中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.